- Text provides cardiologists with an overview of cardiovascular genetics
and genomics -
TORONTO, Aug. 29 /PRNewswire-FirstCall/ - GeneNews Limited (TSX: GEN), a company focused on developing patient-friendly blood-based biomarker tests for the detection and staging of virtually any disease or medical condition, today announced that its co-founder and Chief Scientist Dr. C.C. Liew, has co-edited a newly published genomics reference book entitled Cardiovascular Genetics and Genomics for the Cardiologist. The text provides cardiologists with an overview of cardiovascular genetics and genomics, which have been changing the fundamental understanding of cardiovascular disease and the practice of cardiovascular medicine.
"We are very proud of our Chief Scientist and the inventor of our core technologies, Dr. C.C. Liew. This is not only a significant achievement for Dr. Liew, but also an important and notable contribution to both the field of disease-specific genomics and the field of cardiovascular medicine," said K. Wayne Marshall, MD, PhD, President and Chief Executive Officer of GeneNews. "Dr. Liew is truly a pioneer in disease-specific genomics and has earned a global reputation for his outstanding scientific contributions in this cutting-edge area of healthscience."
Dr. Liew currently holds the positions of Visiting Professor of Medicine and Founding Director of the Cardiovascular Genome Unit at Brigham and Women's Hospital, Harvard Medical School, and Professor Emeritus at the University of Toronto. Genetics and Genomics for the Cardiologist is currently available from the publisher, Blackwell Publishing Inc. (http://www.blackwellcardiology.com).
GeneNews is focused on the application of functional genomics to enable early diagnosis and personalized therapeutic intervention based on disease-specific biomarkers. The Company has developed a novel approach, the Sentinel Principle(TM), to detect and stage virtually any disease or medical condition from a simple blood sample. GeneNews is currently applying the Sentinel Principle(TM) in major areas with unmet clinical needs such as cancer, arthritis, cardiovascular disease and neurological disorders. GeneNews' first product in development, ColonSentry(TM), is a convenient and patient-friendly blood-based biomarker test that can detect colon cancer. For more information on GeneNews, visit http://www.genenews.com.
This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.
|SOURCE GeneNews Limited|
Copyright©2007 PR Newswire.
All rights reserved